<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (BE) is a <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesion</z:e> characterized by replacement of <z:mpath ids='MPATH_458'>normal</z:mpath> squamous epithelium with columnar epithelium </plain></SENT>
<SENT sid="1" pm="."><plain>This lesion can progress to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Recently, the Fas receptor and <z:hpo ids='HP_0009919'>retinoblastoma</z:hpo> (Rb) protein have been described as important mediators of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppression, respectively </plain></SENT>
<SENT sid="3" pm="."><plain>This study was undertaken to examine their expression during the progression of <z:mpath ids='MPATH_160'>metaplasia</z:mpath> to <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> in BE </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: In a review of 56 <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> arising in BE, the specimen blocks were examined using the immunohistochemical avidin-<z:chebi fb="1" ids="15956">biotin</z:chebi>-peroxidase complex technique </plain></SENT>
<SENT sid="5" pm="."><plain>For each specimen, areas of <z:mpath ids='MPATH_458'>normal</z:mpath> epithelium were compared with areas of <z:mpath ids='MPATH_160'>metaplasia</z:mpath>, <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, or <z:mp ids='MP_0002038'>carcinoma</z:mp> (when present) </plain></SENT>
<SENT sid="6" pm="."><plain>Monoclonal mouse anti-human antibodies were used to identify Rb protein (Rb-Ab5, 1/50 dilution; Oncogene Science) and the 40-50-kDa cell membrane Fas protein (<z:chebi fb="16" ids="53704">APO</z:chebi>-1/Fas, 1/5 dilution; DAKO Corp.) </plain></SENT>
<SENT sid="7" pm="."><plain>RESULTS: Loss of Rb staining was observed as the <z:mpath ids='MPATH_160'>metaplasia</z:mpath> progressed to <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0002038'>carcinoma</z:mp>, indicating accumulation of unstainable aberrant protein </plain></SENT>
<SENT sid="8" pm="."><plain>Conversely, Fas protein staining was undetectable or weak in <z:mpath ids='MPATH_458'>normal</z:mpath> or metaplastic epithelium, increasing in the areas of high-grade <z:mpath ids='MPATH_589'>dysplasia</z:mpath> and <z:mp ids='MP_0002038'>carcinoma</z:mp> </plain></SENT>
<SENT sid="9" pm="."><plain>These differences were statistically significant (P &lt; .001) </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: The accumulation of abnormal Rb protein during the progression of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> to <z:mp ids='MP_0002038'>carcinoma</z:mp> leads to unsuppressed <z:e sem="disease" ids="C0598934" disease_type="Neoplastic Process" abbrv="">tumor growth</z:e> </plain></SENT>
<SENT sid="11" pm="."><plain>Fas overexpression may represent a cellular attempt to balance the uncontrolled <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> proliferation by promoting <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
</text></document>